- Home
- RPRX vs XPO Comparison
RPRX vs XPO Comparison
Compare RPRX & XPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- XPO
- Stock Information
- Founded
- RPRX 1996
- XPO 2000
- Country
- RPRX United States
- XPO United States
- Employees
- RPRX N/A
- XPO N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- XPO Transportation Services
- Sector
- RPRX Health Care
- XPO Consumer Discretionary
- Exchange
- RPRX Nasdaq
- XPO Nasdaq
- Market Cap
- RPRX 14.2B
- XPO 14.3B
- IPO Year
- RPRX 2020
- XPO N/A
- Fundamental
- Price
- RPRX $34.02
- XPO $128.14
- Analyst Decision
- RPRX Strong Buy
- XPO Strong Buy
- Analyst Count
- RPRX 4
- XPO 17
- Target Price
- RPRX $42.50
- XPO $134.82
- AVG Volume (30 Days)
- RPRX 3.9M
- XPO 2.2M
- Earning Date
- RPRX 05-08-2025
- XPO 04-30-2025
- Dividend Yield
- RPRX 2.59%
- XPO N/A
- EPS Growth
- RPRX 37.60
- XPO 60.50
- EPS
- RPRX 2.45
- XPO 3.25
- Revenue
- RPRX $2,263,845,000.00
- XPO $8,008,000,000.00
- Revenue This Year
- RPRX $31.16
- XPO $0.93
- Revenue Next Year
- RPRX $5.86
- XPO $4.42
- P/E Ratio
- RPRX $13.85
- XPO $39.42
- Revenue Growth
- RPRX 1.13
- XPO 1.95
- 52 Week Low
- RPRX $24.05
- XPO $85.06
- 52 Week High
- RPRX $34.20
- XPO $161.00
- Technical
- Relative Strength Index (RSI)
- RPRX 61.77
- XPO 68.55
- Support Level
- RPRX $32.18
- XPO $124.00
- Resistance Level
- RPRX $34.11
- XPO $128.64
- Average True Range (ATR)
- RPRX 0.82
- XPO 4.09
- MACD
- RPRX 0.09
- XPO 2.80
- Stochastic Oscillator
- RPRX 91.93
- XPO 96.48
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. we estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. we believe XPO intends to divest its European trucking division once it finds the right buyer.